Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics

Ulcerative Colitis Clinical Trial

Official title:

Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06109441
• Other study ID #: ALTB-268-201
• Status: Recruiting
• Phase: Phase 2
• Start date: December 4, 2023
• Est. completion date: March 2026

Study information

• Verified date: June 2024
• Source: AltruBio Inc.
• Contact: Simona Reed, PhD
• Phone: 17142150224
• Email: simona.reed[@]altrubio.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, and a Maintenance Phase.

Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268 followed by weekly doses of ALTB-268 for 12 weeks. Primary efficacy endpoint will be evaluated at week 12.

Week 12 dosing will occur during the 40 wks Maintenance Phase.

During 40 weeklong maintenance phase SC doses of ALTB-268 will be administered every other week. At week 52, all subjects will have an endoscopy performed and efficacy and safety evaluation will take place.

Description:

ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC.

The study consists of a Screening Phase, an Induction Phase, and a Maintenance Phase. Upon successful completion of the Screening Phase, subjects will return to the clinic for their first visit, which must occur within 28 days of SV1. Eligible subjects will be enrolled to receive a SC loading dose of ALTB-268. followed by a weekly maintenance dose of ALTB-268 in the 12 week Induction Study Phase. During the Induction Phase, study participants will be evaluated weekly at V0 (Day 1), V1 (Week 1), V2 (Week 2), V3 (Week 3), V4 (Week 4), V5 (Week 5), V6 (Week 6), V7 (Week 7), V8(Week 8), V9 (Week 9), V10 (Week 10), and V11 (Week 11) and V12 (Week 12; End of Induction Phase). Participants entering the maintenance study phase will continue to receive the SC dose of ALTB-268 every two weeks, up to week 52. Upon completion of the maintenance study phase, study participants will be asked to return for an end of study visit in approximately 4 weeks, for end of study visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: March 2026
• Est. primary completion date: April 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Adult participants 18 to 75 years old, inclusive, at Screening.

2. Willing to provide informed consent and to be compliant with the schedule of study visits and protocol assessments.

3. Diagnosis of UC established at least 12 weeks prior to Screening by standard clinical and endoscopic evidence and corroborated by a histopathology report.

4. Moderately to severely active UC, at the time of Screening, defined as a modified Mayo Score (mMS) of 5-9, inclusive, with an endoscopic subscore of = 2 (from central reading), and a rectal bleeding (RB) subscore of = 1.

5. Evidence of active UC, extending proximal to the rectum with = 15 cm of involved colon.

6. Stable doses of concomitant medications:

1. Subjects receiving oral corticosteroids for the treatment of UC must be on a stable dose of = 20 mg/day (prednisone or equivalent), or = 9 mg/day budesonide. This dose must be stable from 4 weeks prior to Screening until the end of the Induction Phase.

2. Subjects receiving oral 5-aminosalicylic acid (5-ASA) must be on a stable dose from 4 weeks prior to Screening until the end of study.

3. Subjects receiving immunosuppressants (azathioprine, 6-mercaptopurine [6-MP] or methotrexate) must be on a stable dose for 4 weeks prior to Screening until the end of study treatment. Subjects taking methotrexate are also advised to take folic acid 5 mg/week (or equivalent) if there is no contraindication.

4. Subjects receiving probiotics must be on a stable dose for = 2 weeks prior to Screening until the end of study.

5. Subjects receiving an anti-diarrhetic must be on a stable dose for = 2 weeks prior to Screening until the end of study.

7. Previous treatment with at least one biologic therapy that demonstrated an inadequate response and/or loss of response.

8. Negative pregnancy test during Screening and Day 1 (V0) in females of childbearing potential.

9. Females with reproductive potential must be sexually abstinent or be willing to use a highly effective method of contraception from study start to = 3 months after the final dose of the study drug. Highly effective methods of contraception include:

1. Hormonal contraceptives (e.g., combined oral contraceptives, patch, vaginal ring, injectables, and implants); male partner should use a condom;

2. Intrauterine device or system; or

3. Surgical sterilization or partner sterile (must have documented proof).

10. Male subjects must be either surgically sterile (must have documented proof), agree to be sexually abstinent, or use a double-barrier method of birth control (e.g., condom and diaphragm with spermicide, condom with cervical cap and spermicide) from first study drug administration to = 3 months after the final dose administration.

11. Male subjects must agree to refrain from donating sperm from first study drug administration to = 3 months after final dose administration.

Exclusion Criteria:

1. Diagnosis of Crohn's colitis, colitis yet to be classified, ischemic colitis, nonsteroidal anti-inflammatory drug (NSAID)-induced colitis, idiopathic colitis (i.e., colitis not consistent with UC), or radiation-induced colitis.

2. Ulcerative colitis limited to the rectum (ulcerative proctitis).

3. Presence of short bowel syndrome.

4. History of colectomy, or presence of an ileostomy or colostomy.

5. History of, or active colonic mucosal dysplasia.

6. Treatment with any intravenous (IV) corticosteroid or rectal therapy during the Screening period.

7. Treatment with any calcineurin inhibitor (e.g., cyclosporine, tacrolimus) within 4 weeks prior to Screening.

8. Treatment with NSAIDs within 4 weeks prior to Screening. Short-term use (<7 days) of NSAIDs for non-UC related symptoms is allowed.

9. Treatment with tofacitinib or other Janus Kinase (JAK) inhibitors within 4 weeks prior to Screening.

10. Treatment with sphingosine-1-phosphate receptor (S1PR) modulators within 4 weeks prior to Screening.

11. Biologic therapy within 56 days or 5 half-lives (whichever is longer) prior to Screening. Confirmation of undetectable or non-therapeutic serum levels, as assessed by the Investigator, will allow for eligibility.

12. Tube feeding, defined formula diets, or parenteral alimentation/nutrition within 3 weeks of first dosing.

13. Treatment with oral antibiotics within 4 weeks prior to Screening or IV antibiotics within 8 weeks prior to Screening.

14. Vaccination with a live or live-attenuated vaccine within 4 weeks prior to Screening.

15. History of dysplasia or malignancy in the past 5 years, except completely excised basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.

16. Subjects with a current or recent history of severe, progressive, or uncontrolled cardiac (including uncontrolled hypertension), renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological (e.g., history of seizures) disease, or any other severe comorbidity that, in the opinion of the Investigator, could confound the study results or put the subject at unreasonable risk.

17. Significant screening electrocardiogram (ECG) abnormalities, including evidence of acute myocardial infarction, complete left bundle branch block, second-degree heart block, or complete heart block.

18. For males, a QTc interval (Fridericia's correction) of >450 ms, and for females, a QTc interval (Fridericia's correction) of >470 ms.

19. Any of following laboratory abnormalities during the Screening period. If values are initially outside prescribed limits, the evaluation may be repeated once within the

Screening period to determine eligibility:

1. Calculated creatinine clearance < 60 mL/min

2. Serum transaminases > 2.0x Upper Limit Normal (ULN)

3. Alkaline phosphatase (ALP) > 2.0x ULN

4. Bilirubin > 1.5x ULN; does not apply to subjects with Gilbert's Syndrome (Meulengracht Syndrome)

5. Hemoglobin < 8g/dL

6. Platelets < 75,000/µL

7. Absolute neutrophil count < 1,500/ µL

8. Absolute lymphocyte count < 800/ µL

20. Human immune deficiency virus (HIV) infection or known HIV-related malignancy.

21. Acute or chronic hepatitis B (HBV) or hepatitis C (HCV), or carrier status. Subjects with anti-HBc (hepatitis B core) antibodies (Ab) but with undetectable anti-HBs (hepatitis B surface) Ab should be excluded.

22. Positive immunoglobulin M (IgM) Ab titers in the presence of negative immunoglobulin G (IgG) Ab titers to Epstein-Barr virus (EBV).

23. Positive stool test for ova or parasites, positive stool culture for pathogens, or positive stool toxin assay for Clostridium difficile at Screening.

24. Active cytomegalovirus (CMV) infection at Screening, as assessed by the Investigator.

25. Positive QuantiFERON® TB test at Screening for latent Mycobacterium tuberculosis (TB) infection. If a QuantiFERON® TB test is indeterminate, the test should be repeated. If the result is again indeterminate, the subject should be excluded.

Subjects with a history of latent TB infection who received or are receiving an appropriate and documented course of therapy can be included if the screening examination and a chest x-ray performed within 3 months prior to Screening revealed no evidence of current active infection.

26. History of any opportunistic infection within 12 weeks of first dosing.

27. Any current or recent symptoms/signs of infection, except nasopharyngitis, within 4 weeks of first dosing.

28. Cirrhosis or active alcohol abuse, pr the judgment of the Investigator.

29. History of drug abuse according teo the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria within 12 months prior to Screening or a positive drug screening test.

30. Currently breast feeding, or pregnant.

31. Known hypersensitivity or intolerance to ALTB-268 or any of its excipients.

32. Participation in another clinical trial AND having received investigational medication within 30 days or 5 half-lives (whichever is longer) prior to Screening or having used an investigational device treatment within 30 days prior to Screening. Concurrent participation in an observational or long-term follow-up study and not actively receiving an investigational drug or device treatment may be eligible for participation in this study.

33. Inability to comply with the study protocol, in the opinion of the Investigator.

Related Conditions & MeSH terms

• Colitis
• Colitis, Ulcerative
• Ulcer
• Ulcerative Colitis

Intervention

Biological:
• ALTB-268
ALTB-268 drug product (DP) for SC injection is supplied as a sterile and preservative-free frozen solution or lyophilized powder. All excipients used in the DP formulation are of multi-compendial quality and have precedence for use in parenteral products.

Locations

Country	Name	City	State
Canada	Toronto Immune and Digestive Health Institute Inc.	Toronto	Ontario
Canada	Toronto Digestive Disease Associates Inc.	Vaughan	Ontario
United States	Dayton Gastroenterology, LLC	Beavercreek	Ohio
United States	DHAT / GI Aliance	Garland	Texas
United States	Gastro Health Partners Louisville	Louisville	Kentucky
United States	Caprock Gastro Reasearch	Lubbock	Texas
United States	GI Alliance	Mansfield	Texas
United States	Gastro Health Partners Southern Indiana	New Albany	Indiana
United States	Icahn School of Medicine at Mount Siani	New York	New York
United States	New York Presbyterian Hospital - Weill Cornell Medical Colllege	New York	New York
United States	Digestive and Liver Center of Florida, LLC	Orlando	Florida
United States	Gastroenterology Associates of North Mississippi	Oxford	Mississippi
United States	Southern Star Research Institute LLC	San Antonio	Texas
United States	San Diego Gastroenterology	San Diego	California
United States	Alliance Clinical Research of Tampa, LLC.	Tampa	Florida
United States	Tyler Research Institute	Tyler	Texas
United States	Frontier Clinical Research, LLC	Uniontown	Pennsylvania
United States	GI Alliance	Webster	Texas
United States	Gastro Associates of Florida / GI Alliance	Wellington	Florida

Sponsors (1)

Lead Sponsor	Collaborator
AltruBio Inc.

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Immunogenicity	Immunogenicity (Anti Drug Antibody - ADA) of ALTB-268 will be evaluated by a qualitative bridging immunoassay with electrochemiluminescence detection	week 12 and week 52
Primary	Efficacy - change in mMS at week 12	Change from baseline in mMS at Week 12. The modified Mayo score (mMayo Score) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.	week 12
Secondary	Efficacy - proportion of subjects with clinical response at week 12 and week 52	The proportion of subjects with clinical response at Week 12 and Week 52, defined as a decrease from baseline in the mMS of = 2 points AND at least a 30% reduction from the baseline score, AND a decrease in the RB subscore of = 1 point or an absolute RB score of 0 or 1.; The modified Mayo score (mMayo) is a measure of disease activity in UC. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.	week 12 and week 52
Secondary	Efficacy - proportion of subjects with clinical remission at week 12 and week 52	The proportion of subjects with clinical remission at Week 12 and Week 52, defined as mMS of = 2 points, with a SF subscore of = 1 point, a RB subscore of 0, and an endoscopic subscore of = 1 point.; The modified Mayo score (mMayo) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC. A mMS of 0 or 1 means remission.	week 12 and week 52
Secondary	Efficacy - proportion of subjects with endoscopic improvement at week 12 and week 52	The proportion of subjects with endoscopic improvement, defined as a centrally read endoscopy score of =1 at Week 12 and Week 52.; Endoscopic subscore 0-3: 0 (normal of inactive disease), 1 mild disease (erythema, decreased vascular pattern and mild friability); 2 moderate disease (mark erythema, lack of vascular pattern, friability and erosions); 3 sever disease (spontaneous bleeding and ulceration); Lower score means improvement.	week 12 and week 52
Secondary	Efficacy -proportion of subjects with endoscopic remission at week 12 and week 52	The proportion of subjects with endoscopic remission, defined as a centrally read endoscopy score of 0 at Week 12 and Week 52; Endoscopic subscore 0-3: 0 (normal of inactive disease), 1 mild disease (erythema, decreased vascular pattern and mild friability); 2 moderate disease (mark erythema, lack of vascular pattern, friability and erosions); 3 sever disease (spontaneous bleeding and ulceration); Lower score means improvement. Endoscopic score 0 indicates remission.	week 12 and week 52
Secondary	Efficacy - histological remission, defined as a Robarts Histopathology Index (RHI)	Histological remission, defined as a Robarts Histopathology Index (RHI) Score of = 3 at Week 12 and Week 52; . Robarts Histopathology Index (RHI) measures histological disease activity in ulcerative colitis. RHI ranges from 0-12, with higher score indicating more active disease. Histological remission corresponds with the score 3 or less.	week 12 and week 52
Secondary	Efficacy- change from baseline in RHI score at Week 12 and Week 52	Change from baseline in RHI score at Week 12 and Week 52; Histological remission, defined as a Robarts Histopathology Index (RHI) Score of = 3 at Week 12 and Week 52; Robarts Histopathology Index (RHI) measures histological disease activity in ulcerative colitis. RHI ranges from 0-12, with higher score indicating more active disease. Histological remission corresponds with the score 3 or less.; The lower score means improvement.	week 12 and week 52
Secondary	Efficacy - Histological remission, defined as a Geboes score of = 2	Histological remission, defined as a Geboes score of = 2 at Week 12 and Week 52.; The original Geboes grade system is from Grade 0 to Grade 5.; The following are the grades: Grade 0: Architectural changes Grade 1: Chronic inflammatory infiltrate Grade 2A: Eosinophils in lamina propria Grade 2B: Neutrophils in lamina propria Grade 3: Neutrophils in epithelium Grade 4:Crypt destruction Grade 5: Erosions and ulcerations; The lower score means improvement.	week 12 and week 52
Secondary	Efficacy -Change from baseline in mMS	Change from baseline in mMS at Week 52; The modified Mayo score (mMayo Score) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.	week 52
Secondary	Efficacy - proportion of subjects with corticosteroid free clinical remission	The proportion of subjects with corticosteroid-free clinical remission at Week 52 in subjects receiving corticosteroids on the first day of dosing and electing to undergo corticosteroid tapering during the Maintenance Phase	week 52
Secondary	Efficacy - proportion of subjects with corticosteroid free clinical response	The proportion of subjects with corticosteroid-free clinical response at Week 52 in subjects receiving corticosteroids on the first day of dosing and electing to undergo corticosteroid tapering during the maintenance phase.	week 52
Secondary	Efficacy - change in mMS	Change in individual mMS subscores; The modified Mayo score (mMayo Score) is a measure of disease activity in ulcerative colitis. It is based on stool frequency (SF), rectal bleeding (RB), and endoscopic subscore (ES). The mMS ranges from 0 to 9. A lower mMS means less severe UC, and a higher mMS means more severe UC.	week 12 and week 52
Secondary	Efficacy - change in IBDQ score	15. Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) score at Week 12 and Week 52 The IBDQ is a questionnaire used for an assessment of Health Related Quality of Life (HRQoL) in patients with the Inflammatory Bowel Disease (IBD). The IBDQ has a possible score range of 32 (minimum) to 224 (maximum), where a higher score indicates better HRQoL. The outcome measure is assessed by comparing each patient's change in individual IBDQ score from Baseline to Week 12, and from Baseline to Week 52.	week 12 and week 52